Korro Bio, Inc. Investment Income, Interest
Korro Bio, Inc. (KRRO) reported Investment Income, Interest of $448.00 thousand for the 3-month period ending 2023-09-30, per its 10-Q filed 2023-11-02.
Discontinued › Income Statement › Other Income
us-gaap:InvestmentIncomeInterest · last filed 2023-11-02
- Korro Bio, Inc. investment income, interest for the quarter ending 2023-09-30 was $448.00K, a 27.64% increase year-over-year.
- Korro Bio, Inc. investment income, interest for the quarter ending 2023-06-30 was $346.00K, a 18.59% decline year-over-year.
- Korro Bio, Inc. investment income, interest for the quarter ending 2023-03-31 was $523.00K, a 450.53% increase year-over-year.
- Korro Bio, Inc. investment income, interest for the quarter ending 2022-12-31 was $456.00K, a 456.10% increase year-over-year.
- Korro Bio, Inc. investment income, interest for fiscal 2022 was $1.33M, a 234.26% increase from fiscal 2021.
- Korro Bio, Inc. investment income, interest for fiscal 2021 was $397.00K, a 60.06% decline from fiscal 2020.
- Korro Bio, Inc. investment income, interest for fiscal 2020 was $994.00K, a 44.28% decline from fiscal 2019.
- Korro Bio, Inc. investment income, interest for fiscal 2019 was $1.78M.
| Period end | Investment Income, Interest 3 month | Investment Income, Interest 6 month | Investment Income, Interest 9 month | Investment Income, Interest 12 month |
|---|---|---|---|---|
| 2023-09-30 | $448.00K 10-Q · filed 2023-11-02 | $794.00K derived: sum of 2 quarters · filed 2023-11-02 | $1.32M 10-Q · filed 2023-11-02 | $1.77M derived: sum of 4 quarters · filed 2023-11-02 |
| 2023-06-30 | $346.00K 10-Q · filed 2023-08-10 | $869.00K 10-Q · filed 2023-08-10 | $1.32M derived: sum of 3 quarters · filed 2023-08-10 | $1.68M derived: sum of 4 quarters · filed 2023-11-02 |
| 2023-03-31 | $523.00K 10-Q · filed 2023-05-12 | $979.00K derived: sum of 2 quarters · filed 2023-05-12 | $1.33M derived: sum of 3 quarters · filed 2023-11-02 | $1.75M derived: sum of 4 quarters · filed 2023-11-02 |
| 2022-12-31 | $456.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-10 | $807.00K derived: sum of 2 quarters · filed 2023-11-02 | $1.23M derived: sum of 3 quarters · filed 2023-11-02 | $1.33M 10-K · filed 2023-03-10 |
| 2022-09-30 | $351.00K 10-Q · filed 2023-11-02 | $776.00K derived: sum of 2 quarters · filed 2023-11-02 | $871.00K 10-Q · filed 2023-11-02 | $953.00K derived: sum of 4 quarters · filed 2023-11-02 |
| 2022-06-30 | $425.00K 10-Q · filed 2023-08-10 | $520.00K 10-Q · filed 2023-08-10 | $602.00K derived: sum of 3 quarters · filed 2023-08-10 | $774.00K derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $95.00K 10-Q · filed 2023-05-12 | $177.00K derived: sum of 2 quarters · filed 2023-05-12 | $349.00K derived: sum of 3 quarters · filed 2023-05-12 | $467.00K derived: sum of 4 quarters · filed 2023-05-12 |
| 2021-12-31 | $82.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-10 | $254.00K derived: sum of 2 quarters · filed 2023-03-10 | $372.00K derived: sum of 3 quarters · filed 2023-03-10 | $397.00K 10-K · filed 2023-03-10 |
| 2021-09-30 | $172.00K 10-Q · filed 2022-11-08 | $290.00K derived: sum of 2 quarters · filed 2022-11-08 | $315.00K 10-Q · filed 2022-11-08 | $347.00K derived: sum of 4 quarters · filed 2022-11-08 |
| 2021-06-30 | $118.00K 10-Q · filed 2022-08-09 | $143.00K 10-Q · filed 2022-08-09 | $175.00K derived: sum of 3 quarters · filed 2022-08-09 | $249.00K derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | $25.00K 10-Q · filed 2022-05-04 | $57.00K derived: sum of 2 quarters · filed 2022-05-04 | $131.00K derived: sum of 3 quarters · filed 2022-05-04 | $309.00K derived: sum of 4 quarters · filed 2022-05-04 |
| 2020-12-31 | $32.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15 | $106.00K derived: sum of 2 quarters · filed 2022-03-15 | $284.00K derived: sum of 3 quarters · filed 2022-03-15 | $994.00K 10-K · filed 2022-03-15 |
| 2020-09-30 | $74.00K 10-Q · filed 2021-11-15 | $252.00K derived: sum of 2 quarters · filed 2021-11-15 | $962.00K 10-Q · filed 2021-11-15 | $1.90M derived: sum of 4 quarters · filed 2021-11-15 |
| 2020-06-30 | $178.00K 10-Q · filed 2021-08-12 | $888.00K 10-Q · filed 2021-08-12 | $1.83M derived: sum of 3 quarters · filed 2021-08-12 | $2.45M derived: sum of 4 quarters · filed 2021-08-12 |
| 2020-03-31 | $710.00K 10-Q · filed 2021-05-13 | $1.65M derived: sum of 2 quarters · filed 2021-05-13 | $2.28M derived: sum of 3 quarters · filed 2021-05-13 | $2.40M derived: sum of 4 quarters · filed 2021-05-13 |
| 2019-12-31 | $942.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-29 | $1.57M derived: sum of 2 quarters · filed 2021-03-29 | $1.69M derived: sum of 3 quarters · filed 2021-03-29 | $1.78M 10-K · filed 2021-03-29 |
| 2019-09-30 | $624.00K 10-Q · filed 2020-11-16 | $743.00K derived: sum of 2 quarters · filed 2020-11-16 | $842.00K 10-Q · filed 2020-11-16 | |
| 2019-06-30 | $119.00K 10-Q · filed 2020-08-12 | $218.00K 10-Q · filed 2020-08-12 | ||
| 2019-03-31 | $99.00K 10-Q · filed 2020-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |